https://www.selleckchem.com/products/dansylcadaverine-monodansyl-cadaverine.html This study aimed to evaluate the clinical usefulness of the aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) and modified FIB-4 (m FIB-4) indices in predicting hepatocellular carcinoma (HCC) in patients receiving entecavir (ETV) treatment. Among 1955 patients treated with ETV, a total of 857 treatment-naive CHB patients (liver cirrhosis [LC] 424, non-cirrhosis 433) treated with ETV for >1 year were analyzed. Of the 857 patients, 85 (9.9%) patients (77 in LC group and 8 in non-LC group) developed HCC during the follow-up period. The median observation period was 6.9 years. Multivariate regression analysis of HCC incidence revealed that the initial mFIB-4 index (Hazard ratio [HR] 1.058, 95% confidence interval [C.I.] 1.007 - 1.112, P = 0.027) and the improvement in the FIB-4 index after 1-year of ETV treatment (HR 0.531, 95% C.I. 0.339 - 0.831, P = 0.006) were independent prognostic factors in the entire cohort. In the LC group, the improvement of the FIB-4 index following ETV treatment (HR 0.491, 95% CI 0.280 - 0.861, P = 0.013) was negatively correlated with incidence of HCC. However, the AUROC of specific cut-off values of the FIB-4 index at baseline and 1 year after ETV treatment were 0.572 (95% CI, 0.504-0.640) and 0.615 (95% CI, 0.546 - 0.684), respectively. In the non-LC group, none of the invasive fibrosis indices could not predict HCC incidence. The specific cut-off value of the FIB-4 index was not suitable for predicting HCC. However, the improvement in the FIB-4 index after 1-year of ETV therapy could be a predictor of HCC development in cirrhotic patients. This article is protected by copyright. All rights reserved. The specific cut-off value of the FIB-4 index was not suitable for predicting HCC. However, the improvement in the FIB-4 index after 1-year of ETV therapy could be a predictor of HCC development in cirrhotic patients. This article is protected by